Mark Zuckerberg and Priscilla Chan announced a new Biohub initiative that integrates EvolutionaryScale’s AI team and aligns frontier compute with experimental biology to accelerate disease prevention and cures. The EvolutionaryScale researchers will join Biohub’s science program under Alex Rives, and the organization plans to scale compute toward 10,000 GPUs by 2028 to support large biological models. Biohub framed the move as building the datasets, instrumentation and modeling capabilities needed for next‑generation biological AI — combining imaging, experimental automation and large models to drive discovery. The plan includes consolidation of teams, expanded infrastructure and a philanthropic commitment to long‑term research. The initiative signals growing private investment in AI‑first biology platforms and may shift talent and compute resources into non‑commercial, mission‑driven research; commercial players and academic labs will watch for dataset and tooling spin‑offs that could impact drug discovery pipelines.